CRVO CervoMed, Inc. Total Business Assets

CRVO (CervoMed Inc) - company brandmark

CervoMed Inc. (CRVO) brings together talented neurobiologists, creating an intellectual environment free of bureaucracy with attractive employee stock options. This asset value chart confirms that the total resource volume is 32.04. The company focuses on mitigating brain inflammation to restore cognitive abilities in patients with Lewy body dementia. The absence of competing drugs in this market provides the potential for rapid growth of the customer base.

Cumulative Company Assets: CervoMed Inc. (CRVO) for 02/21/2024 - 10/31/2026

Analytical breakdowns and data insights for company CervoMed Inc (CRVO)

- stock value and consensus price forecast:
Market Price cervomed.com|CRVO - Price Target Chart
- market capitalization data:
Market Capitalization CervoMed Corporation|CRVO - Enterprise Value
- book capitalization information:
Net Asset Value per Share CervoMed|CRVO - Company Net Assets|Market Capitalization to Book Value Ratio cervomed.com|CRVO - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio CervoMed Inc.|CRVO - Long-Term Debt to Equity|Current Liabilities to Capital CervoMed Corporation|CRVO - Company Aggregate Debts|Debt to Book Value CervoMed Corporation|CRVO - Company Long-Term Debts|Short-Term Debt CervoMed|Intermediate Coverage Ratio cervomed.com
- company profitability and valuation multiples indicators:
CRVO - Net Income
Fundamental valuation:CRVO, cervomed.com
Manufactured products of CervoMed

The total assets of CervoMed Inc. (CRVO) reflect the aggregate volume of resources required to develop blood-brain barrier-crossing inhibitors amidst fierce competition with pharmaceutical behemoths. This metric is calculated via a reverse analysis of return on assets (ROA), which allows for the real-time tracking of capital structure transformation and the assessment of the company's financial stability during the period of patent protection based on changes in balance sheet assets.

Direct competitors

Company Assets biogen.com (BIIB)|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|BHVN (Biohaven Ltd.) - Company Total Assets|Cumulative Company Assets amylyx.com (AMLX)|Company Total Assets TRVI|PRAX - Company Assets|Aggregate Company Assets Anavex Corp AVXL|Aggregate Asset Value CBLL|PRTA: Cumulative Company Assets|ALEC: Aggregate Company Assets|Annexon (ANNX) - Aggregate Company Assets|Company Assets Omeros (OMER)|Aggregate Company Assets Neurogene Corp|Cumulative Company Assets AC Immune Inc (ACIU)|Company Total Assets VYGR|NMRA - Company Assets|Company Total Assets SCLX (Scilex)|TVGN: Total Business Assets|ACOG: Cumulative Company Assets|Aggregate Asset Value CGTX (Cognition Therapeutics Inc.)|IKT: Company Total Assets|SAVA - Company Total Asset Base|Aggregate Company Assets Assertio Holdings|Total Business Assets COYA (Coya)|Company Total Assets VTGN|Cumulative Company Assets ovidrx.com OVID|Acumen Pharmaceuticals - Cumulative Company Assets|Company Total Asset Base Alterity Therapeutics Ltd. (ATHE)|Clene Nanomedicine - Company Total Assets|PepGen Inc. (PEPG) - Cumulative Company Assets|Jupiter Neurosciences (JUNS) - Aggregate Company Assets|Relmada Corp - Aggregate Asset Value|Cumulative Company Assets ANVS|Aggregate Company Assets GRCE|Aggregate Company Assets Firefly Neuroscience (AIFF)|KLTO - Company Assets|Aggregate Company Assets NeuroSense Therapeutics Ltd. NRSN|RVPH: Total Business Assets|MetaVia, Inc. - Company Total Assets|Company Assets neuraxis.com|HSDT (heliusmedical.com) - Cumulative Company Assets|Passage Bio (PASG) - Company Total Assets|Aggregate Company Assets Neuphoria Therapeutics, Inc.|NERV: Aggregate Asset Value|Aggregate Company Assets Athira Pharma, Inc. (ATHA)|ADXN - Company Assets|Company Total Assets ALZN (Alzamend Neuro)|CYCN - Cumulative Company Assets|Protagenic - Company Total Assets|Company Assets Pasithea Therapeutics|cortigent.com (CRGT) - Aggregate Company Assets|avenuetx.com - Aggregate Asset Value|Cumulative Company Assets BCLI|Aggregate Company Assets CARA|Aggregate Company Assets Chromocell Therapeutics Corporation (CHRO)|ELYM - Company Assets|Aggregate Company Assets Intra-Cellular Therapies, Inc. ITCI|LBPH - Cumulative Company Assets|Marinus Pharmaceuticals, Inc. - Company Total Assets|Company Assets NKGen Biotech Inc|NRBO: Company Total Assets|Total Business Assets SAGE|Cumulative Company Assets SNPX|TRVN: Aggregate Asset Value|Company Total Assets VIGL|Company Total Asset Base anewmeds.com|Aggregate Company Assets Cerevel CERE